A 12-week, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of canakinumab in pediatric IVIG-naïve or refractory patients with active Kawasaki disease

Trial Profile

A 12-week, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of canakinumab in pediatric IVIG-naïve or refractory patients with active Kawasaki disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Canakinumab (Primary) ; Canakinumab (Primary)
  • Indications Mucocutaneous lymph node syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 11 Feb 2017 Status changed to discontinued.
    • 11 Feb 2017 This trial was discontinued in Germany (end date: 2017-01-26), according to European Clinical Trials Database.
    • 14 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top